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ABSTRACT
Genetic mutations lead to the production of mutated proteins from which peptides are presented to 
T cells as cancer neoantigens. Evidence suggests that T cells that target neoantigens are the main 
mediators of effective cancer immunotherapies. Although algorithms have been used to predict neoanti-
gens, only a minority are immunogenic. The factors that influence neoantigen immunogenicity are not 
completely understood. Here, we classified human neoantigen/neopeptide data into three categories 
based on their TCR-pMHC binding events. We observed a conservative mutant orientation of the anchor 
residue from immunogenic neoantigens which we termed the “NP” rule. By integrating this rule with an 
existing prediction algorithm, we found improved performance in neoantigen prioritization. To better 
understand this rule, we solved several neoantigen/MHC structures. These structures showed that 
neoantigens that follow this rule not only increase peptide-MHC binding affinity but also create new TCR- 
binding features. These molecular insights highlight the value of immune-based classification in neoanti-
gen studies and may enable the design of more effective cancer immunotherapies.
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The immune system can recognize and destroy cancer cells1 
and CD8+ T cells are a major component in this process.2–5 
The recognition of tumor cells by CD8 + T cells requires at 
least two components: expression of major histocompatibility 
complex class I proteins (MHCI) on the cancer cells and 
tumor-derived antigenic peptides which bind to MHCs. 
T-cell receptors (TCRs) expressed by T cells recognize these 
peptide-MHC complexes (pMHC) on cancer cells and target 
them for destruction.
During the last 25 years, great effort has been made to 
identify the tumor antigens that are targeted by T cells.6 
Cancer antigens can be classified into two broad categories, 
self-antigens which are expressed by some normal tissues but 
are usually expressed at much higher levels by cancer cells (e.g., 
MART-1, HER2, CEA) and nonself-antigens, which include 
antigens derived from oncogenic viruses (e.g., human papillo-
mavirus), or neoantigens derived from somatic mutations in 
cancer cells.7 Neoantigens are not present in normal tissues, 
hence the immune system is not tolerant to them and views 
them as foreign antigens.8,9 The targeting of neoantigens is 
ideal because they are not expressed by normal tissue and 
therefore should not result in “on-target, off-tumor” toxicity 
which can be observed in immunotherapies that target self- 
antigens. Moreover, unlike self-antigens, neoantigens are for-
eign to the immune system and thus highly restricted TCRs 
should exist in patients (i.e., not deleted during thymic 
selection).
Currently, the identification of neoantigen relies on next- 
generation sequencing (NGS) to identify nonsynonymous 
mutations, followed by predicting the theoretical binding of 
the corresponding mutated peptides to the patient’s HLA 
molecule10–16using peptide/MHCI binding prediction algo-
rithms. Binding predictions have been used to narrow down 
and select neoantigen candidates for use in immunotherapy 
approaches as well as to help identify the minimal epitope 
recognized by T cells.7,11,12,14,17–25 However, among the neo-
peptides with predicted MHC binding, only a small portion of 
them are immunogenic and therapeutically relevant.26,27 Other 
parameters beyond peptide-MHC binding affinity could affect 
neoantigen immunogenicity.
It has been hypothesized that TCR:pMHC ternary binding 
events may influence neoantigen immunogenicity. Yadav et al. 
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and Fritsch et al. suggested that the side chains of neoantigen 
mutations pointing toward the TCR would be more immuno-
genic while Duan et al. suggested that neoantigen substitutions 
at MHC anchor positions may be more important.7,18,28 
Recently, Capietto et al. also suggested that the increased 
neoantigen-MHC affinity relative to the corresponding wild- 
type peptide is predictive of immunogenicity.29 However, stu-
dies in this area are still limited due to the lack of large human 
neoantigen datasets and neoantigen-MHC crystal structures. 
Thus, systematic analyses based on human neoantigen data 
and a structural understanding of neoantigen immune proper-
ties are still needed.
Here, we attempted to determine immune features based on 
validated neoantigens after mutation positional classification. 
We found that almost all immunogenic anchor mutated 
neoantigens in our datasets followed a conservative mutation 
orientation (termed the NP rule), rather than other orienta-
tions. Combining this rule with the binding predictor 
NetMHCpan 4.024 could improve the performance of neoanti-
gen prioritization. To provide structural insights of this rule, 
we solved several pMHC structures: the KRAS G12D neoanti-
gens in complex with HLA-C*08:02 and the ineffective mouse 
DPAGT1 peptides in complex with a mouse MHC (H-2 Kb). 
We showed that neoantigens that follow the NP rule could 
generate immune features for T cell recognition. Our data also 
suggest that the antigen exposed surface area may be associated 
with neoantigen immunogenicity.
Materials and methods
Generation of the ineffective neopeptides dataset (IEND)
To generate a length-fitted ineffective neopeptide dataset, 
mutant peptides from RIEND (Raw InEffective Neopeptides 
Dataset) were cleaved into 9 mer and 10 mer containing muta-
tions in silico and performed binding prediction with the 
NetMHCpan 4.0 server.24 This newly generated dataset was 
called the InEffective Neopeptide Dataset (IEND).
The mutant peptides (9 mer and 10 mer) were inputted in 
the NetMHCpan 4.0 Server with custom python scripts. The 
prediction of immunogenic neoantigens relies on 
a recommend cutoff (IC50 < 500 nM) of a predicted MHCI 
binding affinity.
Comparison of amino acid biochemical properties
Amino acid dissimilarity comparison of wild-type and mutant 
amino acids was taken for peptide pairs between immunogenic 
and ineffective cohorts based on the BLOSUM50 matrix.30 This 
matrix provided BLOSUM scores represented the similarity of 
amino acid pairs (higher score indicates more similar). Tails of 
the violins to the range of the data were not trimmed. The 
figure was generated by R. Statistical analyses were calculated 
by Wilcoxon test.
The comparisons of “hydrophobicity”, “polarity”, and “side 
chain bulkiness” scores of mutant amino acids between immu-
nogenic and ineffective cohorts were taken based on indepen-
dent numeric scales.31 Independent numeric scales of each 
property were recorded in Supplementary Tables 1, 3, and 4. 
Related figures were generated by R. Statistical analyses for the 
“hydrophobicity”, “polarity”, and “side chain bulkiness” differ-
ences were performed using Wilcoxon test.
Differential agretopic index (DAI) score calculation
The calculation of DAI was described previously.32 Briefly, 
peptide binding affinity with HLAs was predicted by 
NetMHCpan 4.0. The DAI score of each neoantigen pair was 
calculated by subtraction of the neoantigen predicted IC50 
binding affinity from the corresponding wild-type 
counterparts.
Anchor, MHC-contacting, and TCR-contacting 
positions determination
Anchors were defined for each allele based on the SYFPEITHI 
database33 and the highest information content in the 
NetMHCpan binding motif record.24 The anchor position for 
each entry was cross-validated based on solved HLA structures 
from Protein Data Bank (PDB). We recorded these results as 
“consensus anchor” in IND and IEND (Supplementary Tables 1 
and 3).
Peptide MHC-contacting and TCR-contacting positions 
were determined based on solved peptide-MHC complex struc-
tures. Briefly, the positions of peptides that were proved to be 
non-anchor positions can be divided into MHC-contacting and 
TCR-contacting positions. Based on pMHC structural models 
from PDB, those positions which contact MHC were treated as 
MHC-contacting positions. On the contrary, TCR-contacting 
positions often harbor residues with side chains that point 
toward outside from the pMHC complex and may contact 
with TCRs. The MHC-contacting and TCR-contacting informa-
tion of different HLAs was recorded in IND and IEND.
Antigen library and the determination of HLA anchor 
position preference
The nonameric peptide libraries of 30 HLA alleles were 
obtained from the IEDB database.34 Sequence logos were gen-
erated using the sequence logo generator.35 The threshold for 
preferential amino acids at anchor positions was set to include 
and above 10% based on the nonameric peptide libraries from 
IEDB. Related information was recorded in Supplementary 
Tables 1 and 3.
Combined NP+binding (con NP+B) model building
To combine the NP rule with NetMHCpan 4.0, we used 
a logistic regression algorithm. Analyses were performed 
using the R “glm„ function, as below:
immunogenicity ~ NP + Binding prediction.
Anchor mutated neoantigen data were selected to train the 
model. The performance of this model was shown by the ROC 
curve.
The ROC curve was plotted from the false positive rate 
(FPR) and true positive rate (TPR) values calculated by varying 
the cutoff value (separating the predicted positive from the 
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predicted negative) from high to low. The plots were generated 
in R using the packages ggplot2 and plotROC.
To further test this model, we resampled 50 times. Random 
resampling of the data (two-thirds resampling) was used for 
training. The AUC values were calculated by plotROC package. 
After iteration, the differences of AUC between the four mod-
els were measured using paired t-test in R.
Protein expression, refolding, and purification
Inclusion bodies of HLA heavy chains and β2 M were 
expressed as described previously.36 Briefly, The DNA encod-
ing MHC heavy chain (HLA-C*08:02 and H-2 Kb) and light 
chain (human β2 M and mouse β2 M) was synthesized (Idobio) 
and cloned into pET-22(b) vector (Novagen). The vectors were 
transformed into the E. coli strain BL21 DE3 (Novagen). 
Transformants were selected on Luria broth (LB) agar plates 
containing ampicillin. A single colony was selected and cul-
tured in LB fluid medium with the antibiotics listed above at 
37°C. Upon reaching an optical density OD600 of 0.6, expres-
sion was induced with the addition of 1 mM IPTG. Incubation 
continued at 37°C for 5 h. The cells were harvested by centri-
fugation and then resuspended in PBS buffer with 1 mM PMSF 
at 4°C. The cells were lysed, and the lysate was clarified by 
centrifugation at 10,000 g to collect inclusion bodies. Inclusion 
bodies were harvested and solubilized in 20 mM Tris (Vetec) 
pH 8.0, 8 M urea (Vetec), 1 mM EDTA (BBI life sciences), 
1 mM DTT (Sinopharm chemical reagent) and 0.2 mM PMSF 
(Sinopharm chemical reagent).
Refolding was performed in the presence of MHC heavy 
chain, β2M, and peptides as described previously.37 Briefly, the 
resolubilized heavy chain (60 mg each) and the light chain 
(25 mg each) in the presence of the corresponding peptide 
were added into 1 liter of refolding buffer [100 mM Tris (pH 
8.4), 0.5 mM oxidized glutathione (BBI life sciences), 5 mM 
reduced glutathione (BBI life sciences), 400 mM L-arginine 
(Vetec), 2 mM EDTA (BBI life sciences)]. After 48 h of refold-
ing, the 1 L mixture was transferred into dialysis bags (Spectra) 
and dialyzed against 15 liters of 10 mM Tris buffer (pH 8.0) at 
4°C for 24 h.
Refolded proteins were purified by anion exchange chroma-
tography with Q Sepharose HP (GE Healthcare) column then 
Mono Q column (GE Healthcare) and concentrated by tangen-
tial flow filtration using Amicon Ultra centrifugal filters 
(Merck). For desalination and purification, samples were 
loaded onto a Superdex 200 increase 10/300 GL column (GE 
Healthcare) for size exclusion chromatography. 
Chromatography was taken with BioLogic DuoFlow system 
(Bio-rad) at a flow rate of 1 mL/min. Peak analysis was per-
formed using the ASTRA software package (BioLogic 
Chromatography Systems).
Thermal stability assay
The thermal stability assay was performed in the Real Time 
Detection system (Roche). Each pMHC complex was diluted in 
10 mM Tris-HCl (pH 8.0), 0.1 M NaCl buffer. The experiment 
was performed in triplicates for different pMHC complexes. 
Both pMHC complexes were heated from 10°C to 95°C with 
a heating rate of 1°C per minute. The fluorescence intensity 
was measured with excitation at 530 nm and emission at 555  
nm. The Tm represents the temperature for which 50% of the 
protein is unfolded.
Crystallization, data collection, and processing
Purified pMHC complexes were concentrated to 10 mg/ml for 
crystallization trials before screening using a series of kits from 
Hampton Research. Protein complexes were crystallized by 
sitting drop vapor diffusion technique at 4°C. Single crystals 
of C08-mut9m and C08-mut10m were obtained in the condi-
tion of 0.2 M ammonium acetate, 0.1 M HEPES (pH 6.5), 25% 
w/v polyethylene glycol 3,350. For the H-2 Kb complex, single 
crystals of Kb-8 mV and Kb-8 mL complex were obtained 
when 4% v/v Tacsimate (pH 6.0), 12% w/v Polyethylene glycol 
3,350 was used as the reservoir buffer.
Crystals were transferred to crystallization buffer containing 
20% (w/v) glycerol and flash-cooled in liquid nitrogen imme-
diately. The diffraction data were collected at the Shanghai 
Synchrotron Radiation Facility (Shanghai, China) on beamline 
BL17U1/BL18U1/BL19U1, and processed using the iMosflm 
program.38 Data reduction was performed with Aimless and 
Pointless in the CCP4 software suite.39 All structures were 
determined by molecular replacement using Phaser.40 The 
models from the molecular replacement were built using the 
COOT (Crystallographic Object-Oriented Toolkit) program41 
and subsequently subjected to refinement using Phenix 
software.42 Data collection, processing, and refinement statis-
tics are summarized in Supplementary Table 7. All the struc-
tural figures were prepared using PyMOL (http://www.pymol. 
org) program. The atomic coordinates and structure factors for 
the reported crystal structures have been deposited on the 
Protein Data Bank (PDB; http://www.rcsb.org/pdb/).
Results
Classification of cancer neoantigen/neopeptide data by 
mutation position
We obtained MHCI-related, immunogenic (positive data, 
termed neoantigen) and ineffective (negative data, termed 
neopeptide) clinical human cancer neoantigen/neopeptide 
data from a public database called NEPdb (http://nep.whu. 
edu.cn). Herein, the mutant peptides which proved to induce 
T cell response or led to clinical response in the context of 
certain HLA are termed ‘neoantigen’. The mutant peptides 
which did not induce T cell or clinical response are termed 
‘neopeptide’. The neoantigen-HLA complex is termed ‘neoe-
pitope’. These data were curated from 34 published studies that 
contain neoantigen/neopeptide sequences and relevant HLAs. 
All of the data were tested in in vitro T cell assays or clinical 
therapies.5,12–14,43,11,21,44–54,17,19,55–62,22,63–65
The Immunogenic Neoantigen Dataset (IND) in this study 
contains 128 neoantigens with corresponding MHCIs (Figure. 
1a; Supplementary Table 1). The Raw InEffective Neopeptide 
Dataset (RIEND) contains 11739 neopeptides with corre-
sponding MHCIs (Figure. 1a; Supplementary Table 2). All of 









































Entries 128 11,739 2,883
Anchor Mutated Peptides 29 N 428
Tumor Types 15 11 10
HLA-A 14 15 15
HLA-B 14 20 17
HLA-C 7 15 13
Genes 105 1,929 1,081
















































Figure 1. Immune-based classification of data from the Immunogenic neoantigen dataset (IND) and Ineffective neopeptides dataset (IEND). a, Overview of the IND, RIEND, and IEND 
datasets. b, Donut plots of the percentage of 9mer neoantigen/neopeptides, categorized into three classes based on different mutation positions: anchor mutation, MHC-contacting 
position, and TCR-contacting position (immunogenic data, n =51; ineffective data, n=763). c, Nonameric peptides mutation distribution of three classes (mutated at anchor mutation, 
MHC-contacting position, and TCR-contacting position) from IND and IEND. The frequency of mutation distribution at TCR-contacting position and MHC-contacting position showed 
significant difference (TCR-contacting position, p=0.0378; MHC-contacting position, P=0.0027. n (immunogenic) =51; n (ineffective) =763. Fisher’s exact test). The percentage of 
mutation distribution at the anchor position did not show a significant difference between immunogenic and ineffective data (ns, non-significant). d, Nonameric peptides distribution 
of four subgroups (NN, NP, PN, and PP). A significant difference was observed in the NP group (p=8.247e-06, n=27 (immunogenic); n=425 (ineffective), Fisher’s exact test). e, Pie charts 
represented the percentage of the NP group and non-NP groups in IND and IEND (n (immunogenic) = 27; n (ineffective) =425). f, Receiver operator characteristic (ROC) curve showed 
the performance of four prediction models (DAI score, binary NP rule, binding prediction (Rank% scored by NetMHCpan 4.0), combination of NP rule + binding prediction (Com NP 
+B)) with anchor mutated data (data from IND and IEND, n (immunogenic) = 27; n (ineffective) =425). The AUC (Area Under the ROC Curve) was calculated for each predictive model 
(AUCDAI= 0.632; AUCNP rule =0.701; AUCcom NP-B =0.810; AUC Rank%=0.698).
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majority of them are not in the MHCI-fitted lengths (most 
MHCI binders are 8–11 amino acids in length). To obtain 
negative control for further study, we processed these raw 
ineffective neopeptides into optimal MHC-binding length 
(9 mer and 10 mer) in silico and used the NetMHCpan 4.0 
algorithm for peptide-MHC binding prediction. This pro-
cessed dataset is termed the InEffective Neopeptide Dataset 
(IEND) and contains 2883 entries (Figure. 1a; Supplementary 
Table 3).
A stable pMHC complex is helpful for effective TCR recog-
nition and may induce T cell responses. Thus, neoepitope 
candidates can be prioritized through prediction algorithms 
by eliminating the peptides with weak binding affinity to 
MHCIs. While binding prediction algorithms have been suc-
cessfully used for eliminating candidate neoantigens, the pre-
diction of true positive neoantigens remains quite low.66 
Features beyond MHC-binding affinity are therefore involved 
in neoantigen immunogenicity. Recently, some studies found 
that the TCR:pMHC ternary binding events may influence 
immunogenicity.67,68 However, the underlying immunological 
mechanisms of how the binding events affect clinical outcome 
in patients with cancer remain poorly defined.
To address the above questions, we classified peptides from 
IND and IEND based on the mutation positions with different 
functions during TCR:pMHC binding. Specifically, mutant 
peptides from IND and IEND were categorized in the context 
of MHCs into three categories, with mutations: 1) at anchor 
positions that impact MHC binding; 2) at other MHC- 
contacting positions; and 3) that contact the TCR (i.e., point 
toward TCRs instead of MHCs). The classification was per-
formed by referencing the SYFPEITHI database,33 the 
NetMHCpan antigen-binding motif viewer,24 and pMHC 
structures from the Protein Data Bank database (PDB). The 
classification information is shown in Supplementary Tables 1 
and 3.
We next calculated the percentage of neoantigens in the 
different categories. The immunogenic neoantigens were 
more likely to mutate at TCR-contacting regions and less likely 
to change at MHC-contacting regions as compared to those 
ineffective neopeptides (Figure. 1 b, c), consistent with prior 
reports.7,28 There was no difference in the frequency of neoan-
tigen peptides that mutate at anchor positions in the immuno-
genic neoantigens compared to the ineffective neopeptides 
(Figure.1 c). This suggests that the classification of anchor- 
mutated peptides is not sufficient to distinguish the immuno-
genic neoantigens from the ineffective candidates.
Next, we sought to identify amino acid biochemical proper-
ties that define immunogenicity of neoantigens within the 
category of the “TCR-contacting mutations”. We evaluated 
four biochemical properties of amino acids, including “amino 
acid dissimilarity”, “hydrophobicity”, “polarity”, and “side 
chain bulkiness”, that discriminate between immunogenic 
and ineffective cohorts. First, we defined dissimilarity of pep-
tide pairs (the phrase “peptide pairs” refers to the mutant and 
corresponding wild-type peptide), both for immunogenic and 
ineffective data, by using normalized BLOSUM50 substitution 
matrix.30 Next, “hydrophobicity”, “polarity”, and “side chain 
bulkiness” properties were analyzed for mutations across 
immunogenic and ineffective cohorts using independent 
numeric scales described by Chowell et al. (Supplementary 
Table. 4).31 We found no significant difference for the four 
properties between immunogenic and ineffective cohorts 
(Supplementary Fig. 1). Thus, in our datasets, we found that 
these four biochemical properties were not predictive for 
neoantigen immunogenicity.
Anchor mutated neoantigens exhibit a conservative 
mutation pattern to acquire immunogenicity
We aimed to further characterize intrinsic immunological 
properties of anchor mutated neoantigens beyond binding 
affinity. MHC molecules have many allelic variants with dif-
ferent binding properties. Thus, the peptides recognized by 
different MHCs are very diverse, with allele-specific amino 
acid preferences. To investigate the preferential binding prop-
erty of HLAs, we set the cutoff threshold above 10% as HLA 
preferential amino acids at anchor positions as described 
previously69,70 Specifically, we considered a call as preferential 
amino acids only if the amino acids at a certain position yielded 
at least a 10% enrichment, based on the binding-peptide 
libraries from IEDB34 (Supplementary Fig. 2, Supplementary 
Table 1 and 3). We classified the impact of a mutation at the 
MHC anchor residues into the following four groups: 1) non- 
preferential to non-preferential residues (NN); 2) non- 
preferential to preferential residues (NP); 3) preferential to 
non-preferential residues (PN); and 4) preferential to prefer-
ential residues (PP) (Figure. 1d; Supplementary Table 5). 
Statistical analysis showed a higher frequency of NP amino 
acid mutations in the immunogenic dataset compared to 
those in the ineffective dataset (Figure. 1d, p = 8.247e-06). 
Interestingly, 26 in 27 (96%) of the immunogenic pairs can 
be classified into the NP group. In contrast, peptide pairs in the 
NN, PN, or PP groups were dramatically less immunogenic 
(Figure. 1e; Supplementary Table 5).
Next, we further analyzed the 1/27 case in the immunogenic 
cohort that did not follow the NP rule. This neoantigen 
(MYADM R30W, derived from the MYADM protein) has 
a mutation at the C-termini of the peptide.44 Notably, the 
T-cell response was directed against both the wild-type and 
mutant MYADM peptides which demonstrated that the wild- 
type MYADM peptide can bind to the patient’s HLA and elicit 
an autoreactive T cell response in vivo. Neoantigens that elicit 
T-cell responses that target the corresponding wild-type pep-
tide may be less desirable to target due to the potential for 
normal tissue targeting and tolerance. Overall, our observa-
tions suggest that the NP rule is a conservative feature of 
immunogenic anchor mutated neoantigens.
The NP rule of anchor mutated neoantigens thus can be 
treated as a binary variable (1 = true NP, 0 = false NP). To 
assess whether this variable can be used in neoantigen prior-
itization, we respectively tested the performance of the binary 
“NP” model, and the combination model of this binary model 
with the NetMHCpan 4.0 Rank% model (termed Com NP+B). 
Two prediction models, NetMHCpan 4.0 (using NetMHCpan 
4.0 Rank% score) and the DAI models (differential agretopic 
index, the difference of predicted binding affinity between the 
mutated epitope and its unmutated counterpart) were also 
tested with our data as benchmarks. After calculation, the 
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“Com NP+B” model achieved better performance compared 
with the other three models (Figure. 1 f, AUC = 0.810). When 
comparing the performance of these four predictors, an assess-
ment was also done by 50-fold cross-validation (two-thirds 
random resampling) over the data to check whether the 
observed difference in average AUC differs significantly 
(Supplementary Fig. 3). Collectively, we proved that the NP 
rule can be used as a predictive feature to improve neoantigen 
prioritization.
Anchor mutated neoantigens can generate new 
surface for T cell recognition
To understand how the NP rule forms the basis for under-
standing the immunogenicity of anchor mutated neoantigens, 
we attempted to solve structures of two neoepitopes containing 
the KRAS G12D mutations in complex with HLA-C*08:02 
(C08).12 Targeting of these neoepitopes with the adoptive 
transfer of tumor-infiltrating lymphocytes (TIL) was associated 
with an objective clinical response in a patient with metastatic 
colorectal cancer. The TIL specifically recognized the KRAS 
G12D 9 mer neoantigen GADGVGKSA and the 10 mer neoan-
tigen GADGVGKSAL (both mutated at position 3 on the 
peptides from glycine to aspartic acid), and not the wild-type 
peptides, when presented by HLA-C*08:02. These two neoan-
tigens can be categorized into the NP group (Supplementary 
Table 1).
To investigate the properties of these neoepitopes, we 
performed protein refolding for HLA-C*08:02 (C08) with 
four peptides: the wild-type KRAS 9 mer GAGGVGKSA 
(wt9m); the wild-type KRAS 10 mer peptide 
GAGGVGKSAL (wt10m); the mutant KRAS G12D 9 mer 
peptide GADGVGKSA (mut9m, mutation site is indicated 
with underline), and the mutant KRAS G12D 10 mer peptide 
GADGVGKSAL (mut10m). The C08-mut9m and C08- 
mut10m complexes were successfully obtained by refolding 
in vitro. However, the wt9m and wt10m peptides failed to 
refold with HLA-C*08:02 even with a ten-fold increase in the 
concentration of the peptides. To investigate binding details 
of C08-mut9m and C08-mut10m complexes, we next per-
formed thermal denaturation tests for C08-mut9m and C08- 
mut10m respectively. Both pMHCs exhibited normal and 
similar melting points (C08-mut9m, 50 ± 1.6°C; C08- 
mut10m, 48 ± 1.1°C; Supplementary Table 6). These results 
indicated that mut9m and the mut10m can stabilize the 
pMHC complexes and exhibit similar stability after engaging 
with HLA-C*08:02.
To identify potential structural differences of C08- 
mut9m and C08-mut10m, we solved the crystal structures 
of HLA-C*08:02 in complex with mut9m at 2.4 Å (PDB id: 
6JTP) and mut10m at 1.9 Å (PDB id: 6JTN) 
(Supplementary Table 7). Electron density for peptides 
was unambiguous (Figure. 2a, b). C08-mut9m and C08- 
mut10m showed conservative conformations except for 
the peptide-regions (Figure. 2 c, d). Smaller residues such 
as alanine and serine at peptide P1 and P2 positions are 
preferably selected by HLA-C*08:02 (Figure. 2 e, 
Supplementary Fig. 2) due to the narrow cleft formed by 
several aromatic residues (Tyr7, Phe33, Tyr67, Tyr99, 
Tyr59, Tyr171, Tyr159, and Trp167) which limited the 
size of P1 and P2 (Figure. 2 f).
Generally, peptides use P2 and PΩ as anchor residues to 
occupy the B and F pockets of MHCIs. However, the structures 
of C08-mut9m and C08-mut10m revealed that mut9m and 
mut10m used the unconventional P3 position as an anchor to 
bind HLA-C*08:02 (Figure. 2 g, h). HLA-C*08:02 binds P3D 
via the Arg97 and Arg156 residues. The side chain of P3D in 
C08-mut9m also forms an intra-chain hydrogen bond with 
P4G, while this bond is absent in C08-mut10m. Interestingly, 
we found that the P3D anchor residue in C08-mut9m could 
also provide TCR accessible surface by partially exposing its 
charged side chain (Supplementary Fig. 4). This phenomenon 
suggested that some neoantigens with anchor mutations can 
not only increase pMHC binding force but also provide an 
additional accessible surface for TCR interaction, under certain 
conditions, and therefore affect the interactions with TCRs.
Although mut9m and mut10m occupied the same F pocket 
with their PΩ residues, the P10L side chain from mut10m 
buried deeper than P9A in C08-mut9m (Figure. 2g, h). 
Meanwhile, instead of the TCR-oriented residue P8S on 
mut9m, mut10m uses P8S as an auxiliary anchor to bind 
HLAs via hydrogen bonds to Glu152 and Arg156. This residue, 
together with P3D, squeezed the P4-P7 region of mut10m in 
C08-mut10m (Figure. 2h). Together, the details of TCR- 
binding surfaces are largely different between C08-mut9m 
and C08-mut10m. We postulated that these differences may 
respectively modulate T cell recognition and activate different 
T cell repertoires (discussed below). Meanwhile, structural 
analysis of C08-mut9m and C08-mut10m suggested that 
neoantigens with anchor mutations not only generate new 
immune features but also create novel neoepitope surfaces. In 
one sense, the newly generated neoepitope can be “seen” as 
a totally foreign epitope by T cells. We postulated that the 
anchor mutated neoantigens may be more immunogenic 
than those neoantigens with non-anchor mutations.
Structure of a non-therapeutic neoantigen from 
DPAGT1 in complex with mouse H-2 Kb
Yadav et al. described a neopeptide that can be presented by 
a mouse MHC (H-2 Kb) but showed the ineffective property 
in vivo.7 This mouse DPAGT1 V213L neopeptide contains 
a mutated C-terminal anchor residue that falls into the “pre-
ferential to preferential residues (PP)” group, with the chan-
ging of valine (V) to leucine (L). We next solved the X-ray 
crystal structures of these peptides in complex with H-2 Kb. 
Soluble mouse H-2 Kb in complex with the mutant DPAGT1 
V213L 8mer peptide (SIIVFNLL, termed mut8mL) and the 
wild-type 8mer counterpart (SIIVFNLV, termed wt8mV) 
were separately expressed, refolded, and purified for crystal-
lization trials. Crystal diffraction data of Kb-wt8mV and Kb- 
mut8mL were processed to 2.4 Å and 2.5 Å resolution respec-
tively (Supplementary Table 7) and provided electron density 
for each peptide (Figure. 3a).
The overall structure of Kb-wt8mV closely resembles that of 
Kb-mut8mL except for a slight difference at PΩ (P8) (Figure. 
3b). The PΩ residues acted as anchors in both Kb-wt8mV and 
Kb-mut8mL (Figure. 3b). Moreover, both PΩ valine and 
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leucine were preferably selected by H-2 Kb (Figure. 3 c). Both 
of the two PΩ residues in these structures formed hydrogen 
bonds with Asp77, Tyr84, Thr143, and Lys146 (Figure. 3d, e). 
Although the side chain of leucine in mut8mL inserted deeper 
into Kb than valine in wt8mV because of its longer side chain, 
these two peptides did not provide a different TCR binding 
surface with Kb (Figure. 3 b, d, e). These findings indicated that 













































Figure 2. Structural comparison of the C08-mut9m and C08-mut10m complexes. a-b, Unambiguous 2Fo-Fc electron density maps of the (a) KRAS G12D 9mer (GADGVGKSA, green) 
and (b)10mer (GADGVGKSAL, yellow) neoantigens from the solved structures. The underlined amino acids represented the mutations. c, Overlay of the Cα traces (C08-mut9m, green; 
C08-mut10m, yellow). d, Overlay of the mut9m (green) and mut10m (yellow) peptides. e, Polar interactions at peptide P1G and P2A positions. HLA-C*08:02 showed in grey. The 
mut9m peptide showed in green and mut10m showed in yellow. f, Aromatic residues (green) from HLA-C*08:02, accommodating the P1 and P2 residues from peptides. g, The P3D 
and P9A residues of mut9m peptide interact with HLA-C*08:02. h, The P3D, P8S, and P10LA residues of mut10m peptide interact with HLA-C*08:02.
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binding surfaces and be immunogenic. Ineffectiveness of the 
neopeptides with the PP rule might be explained by the pre-
existence of the wild-type peptide-MHC complex in the thy-
mus, which leads to negative selection of potential neopeptide- 
restricted T cell repertoires. Considering that peptide-MHC 
binding is necessary for neoepitope immunogenicity, we do 
not discuss the situations of the “PN” and “NN” rules.
Neoantigen exposed surface areas may affect T cell 
selection in cancer immunotherapy
Peptide antigens can form stable complexes with HLAs by 
lying within the HLA antigen-binding cleft. Some antigens, 
called “featureless” antigens, have a relatively small exposed 
surface area (ESA) from side chains pointing toward the 
T cell receptor when they engage with HLAs.71 Studies have 
indicated that featureless epitopes are more likely to select 
relatively narrow TCR repertoires than epitopes with large 
exposed features in vivo.72 We next examined the ESA 
feature of C08-mut9m and C08-mut10m, by employing 
the PDBePISA server. Of note, ESAs of two different 
T cell epitopes were also calculated as benchmarks. One is 
HLA-A2–M1, a viral antigen “M1” (M158-66 from the IAV) 
in complex with HLA-A*02:01(A2-M1, in Figure. 4a), 
which is considered a featureless epitope.73 In contrast, 
the viral epitope HLA-A2-RT is a reverse transcriptase 
peptide (RT468-476 from HIV) in complex with HLA-A*02 
:01(called A2-RT, in Figure. 4a), and is considered as 
a largely exposed epitope.74 After calculation, we found 
that mut9m has the smallest ESA at 240 Å2 even less than 
the well-known featureless M1 peptide (251 Å2 in Figure. 
4a-c). However, mut10m has a relatively large ESA at 317 
Å2 which is comparable to the typical largely exposed anti-
gen RT (330 Å2 in Figure. 4a-c). These data suggested that 
mut9m provides relatively less ESA than canonical T cell 











































Figure 3. H-2 Kb presented DPAGT V213L wild-type peptide wt8mV and mutant peptide mut8mL in a similar manner a, Unambiguous 2Fo-Fc electron density maps of 
the DPAGT1 wild-type 8mer peptide (wt8mV peptide SIIVFNLV, magenta) and mutant 8mer peptide (mut8mL peptide SIIVFNLL, orange) from solved structures. b, 
Overlay of the wt8mV (magenta) and mutant mut8mL (orange) peptides. c, Sequence logo of H-2 Kb with 8mer peptides. The peptide library was obtained from IEDB 
(n=4141). d, The anchor residue P8V of wt8mV interacts with H-2 Kb (grey). e, The anchor residue P8L of mut8mL interacts with H-2 Kb (grey).
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mut9m-restricted TCRs may be constrained in vivo because 
of the featureless area available for TCR recognition.
Studies have suggested that only narrow TCR repertoires 
can recognize featureless epitope, because of the lack of 
TCR recognition modes.72,73,75 To observe the diversity of 
KRAS G12D neoantigen-specific TCRs in clinical cases, we 
examined the TCR sequences of those restricted T cell 
repertoires targeting C08-mut9m (Figure. 4d, patients 
3995 and 4095, both expressing HLA-C*08:02).12,57 Patient 
3995 received ACT (adoptive cell transfer) treatments and 
did not respond. In this trial, the transferred cell products 
contain the RK5 (RK herein refers to ‘Restricted KRAS 
G12D mutation’) T cell repertoire which can recognize 
C08-mut9m. Patient 4095 received an ACT treatment and 
observed objective tumor regressions. The RK1, RK3, RK4 
T cell clones from this patient were verified to recognize 
C08-mut9m while the RK2 clone recognized C08-mut10m. 
All these four T cell clones (RK1, RK3, RK4, RK5) with 
C08-mut9m restriction were identified to have biased usage 
of a public TCR pair (TRAV4/TRBV5-1) across two 
patients. The length and sequence of these TCRα chains 
were highly restricted, with the same TCR-V region and the 
“CLVGDxDQAGTALIF” CDR3α motif among the four 
TCRs (Figure. 4d). TCRβ chains were also restricted at 
TCR-V region but showed differences at CDR3β region. 
Generally, the CDR1 and CDR2 loops of TCR can recog-
nize the two conservative α-helixes on the MHC, whereas 
the CDR3 loops mainly interact with the exposed peptide. 
Moreover, CDR3β had proved to be the main factor that 
determines TCR recognition (compared with CDR3α) in 
many cases, due to greater sequence diversity and extensive 

































































527 2699 ND (d+39
pMHC name Peptide PESA (Å^2)
C08-mut9m GADGVGKSA 239.89
C08-mut10m GADGVGKSAL 316.90 
A2-IAV M1 GILGFVFTL 250.96 
A2-HIV RT ILKEPVHGV 329.88 
Figure 4. Different peptide exposed surface area (ESA) between C08-mut9m and C08-mut10m a, Peptide exposed surface area (ESA) of four pMHCs. ESA of A2-IAV M1 
complex was calculated based on 2VLL (PDB ID). ESA of A2-HIV RT complex was calculated based on 2X4U. b, ESA of individual residues at each position of four peptides 
within HLAs. c, Mut10m exhibits relatively large ESA compared to A2-IAV M1 (the featureless benchmark), C08-mut9m, and C08-mut10m. The HLA backbone surface 
was shown in grey. IAV M1 (blue), mut9m (green), and mut10m (yellow) peptide surfaces were shown in different colors.d, Different T cell fates of KRAS G12D 
neoantigen-restricted T cells reported by previous clinical studies. Rank in tumor sample represents the rank of restricted T cells in patient’s TILs before cell therapy. Rank 
in infusion products represents the rank of restricted T cells in cell transfer products before cell transfer. Rank in blood represents the rank of restricted T cells in patients’ 
peripheral blood after cell transfer (d+ represents the day after cell transfer). The rank of T cells with the same TCR pair was validated in one or three different metastatic 
tumor fragments from the patient. *, tested in three fragments; ND, not detected.
ONCOIMMUNOLOGY e1868130-9
C08-mut9m restricted TCR sequences of CDR1, CRR2, and 
CDR3α were found to be consistent across different 
patients. We thus speculated that these public regions of 
CDR1, CDR2, and CDR3α are important in the C08- 
mut9m recognition, rather than the CDR3β regions. In 
contrast, the C08-mut10m neoepitope did not observe 
dominant public TCRs in patient 4095 or across different 
individuals. Collectively, these data suggested that the fea-
tureless mut9m neoepitope can be recognized by T cells 
with public and limited TCRs across different patients.
Previous reports have shown that constrained TCR repertoires 
are associated with poor control of viral infection.76,77 However, 
the correlation between TCR bias and clinical outcome in cancer 
treatment is unclear. In an exploratory analysis, we examined the 
TCR bias and clinical performance in the above cases. The C08- 
mut9m restricted T cell clones with public TCR usage (RK1, RK3 
RK4, and RK5) were not the top ranked clonotypes among the 
TILs (Figure. 4d). However, the RK2 T cells with C08-mut10m 
restriction showed dominant persistence in both TIL and the 
blood after cell transfer. While we did not observe a direct corre-
lation between TCR diversity and clinical outcome due to limita-
tions in these clinical data, we still observed short-lived T cell 
persistence in the presence of the featureless C08-mut9m neoe-
pitope. We thus postulated that cancer patients who receive 
neoantigen-based immunotherapies with characteristic (relatively 
large ESA) neoantigens might obtain neoantigen-restricted T cells 
with better persistence in vivo.
Discussion
How T cells recognize neoantigens as “non-self” is an impor-
tant question in cancer immunotherapy. In contrast to con-
ventional pathogenic peptides that are completely foreign, 
neoantigens can differ from self by only a single amino acid. 
Understanding the factors and mechanisms that contribute to 
the immunogenicity of neoantigens may instruct the design of 
future immunotherapies.
Efforts have been made to understand the complexity of 
neoantigen immunogenicity with a major focus thus far on 
peptide-MHC binding. Different studies have led to different 
conclusions.78 Fritsch et al. and Yadav et al. suggest that 
immunogenic neoantigens are more commonly mutated at 
a TCR-contacting residue, while Duan et al. suggested that 
neoantigen substitutions at MHC anchor residues may be 
more immunogenic.7,18,28 Further, using mouse models, 
Capietto et al. showed that increased affinity relative to the 
corresponding wild-type peptide can influence neoantigen 
immunogenicity.29 We found that mutations occur more fre-
quently at TCR-contacting positions rather than MHC- 
contacting positions in the immunogenic dataset. However, 
amino acid biochemical properties might not be critical for 
neoantigen filtering for candidates with TCR-contacting posi-
tion mutation. For mutations that occur at the MHC anchor 
positions, we showed that the NP rule of anchor mutated 
neoantigens exists pervasively. Also, we found that the NP 
rule combines with the MHC-binding predictor NetMHCpan 
4.0 to enhance the prioritization of neoantigen candidates. In 
a sense, the NP feature could be captured by existing neoanti-
gen predictors through the comparison of binding differences 
between wild-type and mutant peptides.18,79,80 However, the 
NP rule we provide here is a binary feature that can provide 
a direct understanding of neoantigen immunogenicity. 
Nevertheless, the robustness of the NP rule will need to be 
tested with larger sample sizes.
We also performed structural studies to obtain insights 
into the NP rule. We found that anchor mutated neoanti-
gens that followed the NP rule can generate new surfaces 
and features for T cell recognition that the wild-type pep-
tide cannot. In contrast, the anchor mutated neopeptide 
from DPAGT1 with PP rule exhibited low immunogenicity 
in clinical treatment. It is possible that most of the neoe-
pitope restricted T cells were also cross-reactive with wild- 
type and thus were removed by negative selection. Our data 
also suggest that neoantigen exposed surface area (ESA) 
might be a factor that influences TCR diversity and clinical 
outcome, but more experimental data and neoantigen-MHC 
structures are needed to fully understand the relevance 
between ESA and TCR diversity.
Our study showed three possible neoantigen binding mod-
els within the context of MHC (Supplementary Fig. 5). Model 
A represents the situation in which a mutation occurs in the 
peptide that contacts TCR. Model B represents the situation in 
which a mutation occurs at a non-anchor MHC-contacting 
region and therefore might be least immunogenic. Model 
C represents the situation in which a mutation occurs at 
MHC anchor position. Anchor mutations may not change 
the TCR-contacting surface but instead lead to enhanced de 
novo presentation of the peptide for TCR recognition.
KRAS G12D is one of the most common driver mutations 
that leads to oncogenesis.81 It is also indicative of poor prog-
nosis with poor response to standard cancer treatments. The 
transfer of HLA-C*08:02-restricted T cells targeting KRAS 
G12D neoantigens was associated with clinical response. 
Based on these pMHC structures, further research could be 
undertaken to increase the immunogenicity and stability of the 
KRAS G12D-C*08:02 neoepitope, by making modifications of 
agonist peptides or by screening non-natural synthetic 
epitopes.82,83 Our structures could also be used to design arti-
ficial receptors/proteins that bind mutant KRAS peptides based 
on synthetic biology approaches.
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